• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Keytruda (pembrolizumab)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Keytruda (pembrolizumab)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Keytruda (pembrolizumab) is a programmed death receptor-1 (PD 1)-blocking, humanized monoclonal antibody.

    Keytruda is specifically indicated for 1) the  first line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS)≥10] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status and 2) for the second line treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

    Keytruda is supplied as a solution for intravenous injection. The recommended dose of Keytruda is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression. 

    Clinical Results

    FDA Approval

    The FDA approval of Keytruda was based on results from the KEYNOTE-052 Phase 2 trial and the KEYNOTE-045 Phase 3 trial. 

    KEYNOTE-052 included 370 patients with locally advanced or metastatic urothelial carcinoma who were not eligible for Platinol-containing chemotherapy. All participants received Keytruda once every three weeks for up to 24 weeks, unless they presented signs of treatment-related toxicity. The treatment had an objective response rate (ORR) of 29%, including 7% complete responses and 22% partial responses. The duration of response ranged from 1.4 to 17.8 months. At the time of the analysis, less than half of patients who responded had seen their disease progress again, hence the median duration of response was unattainable.

    KEYNOTE-045 was a multicenter, placebo-controlled study in 542 patients with locally advanced or metastatic urothelial carcinoma, whose disease progressed on or after platinum-based chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy. Patients were randomized to receive either Keytruda every three weeks or investigator’s choice chemotherapy. Chemotherapy regimens included Taxol (paclitaxel), Taxotere (docetaxel), or vinflunine. Overall, Keytruda treatment demonstrated a superior overall survival (OS) compared to the other treatment regimens, with a 27% reduction in the risk of death. Keytruda treatment resulted in a median OS of 10.3 months, compared to 7.4 months in the chemotherapy arm. No statistically significant difference in progression-free survival (PFS) was observed between groups, with those receiving Keytruda having a median PFS of 2.1 months, compared to 3.3 months in the chemotherapy arm. Keytruda was also seen to improve objective response rate compared to chemotherapy regimens. The ORR was 21% in the Keytruda-treated group vs. 11% in the chemotherapy group.

    Side Effects

    Adverse effects associated with the use of Keytruda may include, but are not limited to, the following:

    fatigue

    musculoskeletal pain

    decreased appetite

    pruritus

    diarrhea

    nausea

    rash

    pyrexia

    cough

    dyspnea

    constipation

    pain

    abdominal pain

    Mechanism of Action

    Keytruda (pembrolizumab) is a programmed death receptor-1 (PD 1)-blocking, humanized monoclonal IgG4 kappa antibody. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. 

    Additional Information

    For additional information regarding Keytruda or urothelial carcinoma (bladder cancer), please visit https://www.keytruda.com/

    Approval Date: 2017-05-01
    Company Name: Merck
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing